Inclusion Criteria:

1. Aged 18-65 years, male or female
2. Conforming to diagnosis standard of chronic hepatitis B according to"2005 Guideline for Prevention and Treatment of Hepatitis B", (with positive HBsAg for more than 6 months), and HBV-DNA more than 1×10E5 copies/ml；HBeAg (+), HBsAb(-)；ALT within 2 to 10 times of ULN (upper limits of normal)
3. HLA-A2 positive
4. Compensatory liver disease having following hematological and biochemical parameters:WBC≥3.5×10E9/L；ANC≥1.5×10E9/L；PLT≥80×10E9/L；Hb≥110g/L；TBil≤1.5ULN；ALB in normal value；BUN,Cr in normal value；PT elongation≤3 sec;APTT in normal value；Fasting blood glucose≤7.0mmol/L
5. TSH in normal value
6. AFP test result ≤20ng/ml
7. Take effective contraception for subject with child-bearing potential (including females and female partners of males)
8. Understand and sign ICF approved by EC
9. Willing to comply with the study procedures and complete the study

Exclusion Criteria:

1. Antibodies of HAV IgM, HCV, HDV or HEV is positive
2. Antibodies of CMV IgM, EBV IgM or HIV is positive
3. ANA titer＞1:160
4. Hepatocarcinoma, suspected hepatocarcinoma or hepatic cirrhosis
5. Have the following illness or with severe disease inappropriate to participate in the study in the view of the investigator, such as:Cardiovascular system: instable or significant cardiovascular illness such as angina pectoris, heart attack of myocardial infarction, congestive heart failure, severe hypertension, significant arrhythmia or abnormal ECG etc.；Respiratory system: bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, respiratory failure, etc.；Endocrine, metabolism diseases: diabetes mellitus, uncontrolled thyroid diseases, etc.；Others: autoimmune disorder, active tuberculosis, malignancies (e.g.tumor), neuropathic or metal illness history,etc.
6. Have used anti-HBV drug (Interferon, Lamivudine, Adefovir Dipivoxil, Entecavir and Telbivudine) and immunomodulator (Thymopeptides, etc ) 6 months prior to the administration of study medication
7. Have participated in any other drug clinical investigations within 3 months
8. Have allergy habitus or have suspected allergy to study drug
9. Female in pregnance, lactation or those who plan to pregnancy during the course of the study
10. Have history of alcohol abuse (Alcohol consumption for more than 5 years, with daily consumption over 40g for males and over 20g for females) and known drug dependence；
11. Have history of organ transplantation (except corneal transplantation and hair transplantation)；
12. Any other factors inappropriate for enroll in the study or study completion in the view of the investigator.